Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting aurora kinases as therapy in multiple myeloma.

Blood - 1 May 2007

Shi Yijiang, Reiman Tony, Li Weiqun, Maxwell Christopher A, Sen Subrata, Pilarski Linda, Daniels Tracy R, Penichet Manuel L, Feldman Rick, Lichtenstein Alan

Abstract excerpt

The aurora kinases facilitate transit from G2 through cytokinesis and, thus, are targets in cancer therapy. Multiple myeloma (MM) is a malignancy characterized by genetic instability, suggesting a disruption of checkpoints that arrest cells at G2M when injury to the mitotic machinery occurs. Since deficient checkpoints would prevent cell cycle arrest and may render cells susceptible to apoptosis in mitosis and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aurora Kinases
Share to Boronic Acids

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bortezomib

Share to Drug Screening Assays, Antitumor

Share to G2 Phase

Share to Hyaluronan Receptors

Share to Ploidies

Share to Pyrazines

Source

Open in PubMed Open full text

Identifiers

PMID: 17213289
DOI: 10.1182/blood-2006-07-037671
PMCID: PMC1874561

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting aurora kinases as therapy in multiple myeloma.PMID 17213289Read ↗

Aurora A kinase RNAi and small molecule inhibition of Aurora kinases with VE-465 induce apoptotic death in multiple myeloma cellsSemantic proximity Read ↗

Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myelomaSemantic proximity Read ↗

The potential role of Aurora kinase inhibitors in haematological malignanciesSemantic proximity Read ↗

Aurora Kinases as Anticancer Drug TargetsSemantic proximity Read ↗

Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor–induced DNA damage in vitro and in vivo in human multiple myeloma cellsSemantic proximity Read ↗

Non-canonical role for the ataxia-telangiectasia-Rad3 pathway in STAT3 activation in human multiple myeloma cellsSemantic proximity Read ↗

Inhibition of cell cycle progression by dual phosphatidylinositol-3-kinase and mTOR blockade in cyclin D2 positive multiple myeloma bearing IgH translocationsSemantic proximity Read ↗

A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemiaSemantic proximity Read ↗

AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders.Semantic proximity Read ↗

Targeting Ongoing DNA Damage in Multiple Myeloma: Effects of DNA Damage Response Inhibitors on Plasma Cell SurvivalSemantic proximity Read ↗

Mcl-1 Stability Determines Mitotic Cell Fate of Human Multiple Myeloma Tumor Cells Treated with the Kinesin Spindle Protein Inhibitor ARRY-520Semantic proximity Read ↗

Sensitivity of BRCA2 mutated human cell lines to Aurora kinase inhibition.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.